Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022
Retrieved on:
화요일, 10월 11, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, LinkedIn, CDC, AGAF, MBBS, Risk, Yale School of Medicine, Nausea, Therapy, CP, Maternal health, Breakthrough therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Reproductive medicine, Diarrhea, CDI, Twitter, Clostridioides difficile infection, Division, FACG, Multimedia, Fridtjof Nansen Prize for Outstanding Research, Inflammation, Centers for Disease Control and Prevention, Food, Center, ACG, MD, Journal of Managed Care & Specialty Pharmacy, Symptoms of COVID-19, Health, Pain, Ferring Pharmaceuticals, Research, Hepatology, Congress, Safety, EDT, 2021 Essex County Council election, Medication, Recurrence, Fast Track, Fever, Clostridium difficile, Death, Colitis, FDA, American College, Pharmaceutical industry, Medicine, Perfume, Animal, Gastroenterology, Patient
Ferring Pharmaceuticals today announced it will present data from new analyses of RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment.
Key Points:
- Ferring Pharmaceuticals today announced it will present data from new analyses of RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment.
- In addition, data will be presented that measures the physical, mental, and social health-related quality of life in patients with recurrent CDI.
- C. difficile infection (CDI) is a serious and potentially deadly disease that impacts people across the globe.
- Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection.